I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Geoffrey M. Parker net worth and biography

Geoffrey Parker Biography and Net Worth

Director of Perrigo

Geoffrey M. Parker has been a director of Perrigo since November 2016. Since April 2017, Mr. Parker has served as Chief Financial Officer of Tricida, Inc., a biopharmaceutical company. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, a biopharmaceutical company, from September 2010 to May 2015. From 1997 to 2009, Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. Mr. Parker has served as a member of the board of directors of ChemoCentryx since December 2009, respectively. Mr. Parker served on the board of directors of Genomic Health from June 2016 until November 2019 and Sunesis Pharmaceuticals from March 2016 until December 2017.

What is Geoffrey M. Parker's net worth?: The estimated net worth of Geoffrey M. Parker is at least $22.25 million as of January 30th, 2024. Mr. Parker owns 819,590 shares of Perrigo stock worth more than $22,251,869 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Parker may own. Learn More about Geoffrey M. Parker's net worth.
How do I contact Geoffrey M. Parker?: The corporate mailing address for Mr. Parker and other Perrigo executives is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. Perrigo can also be reached via phone at (531) 709-4000 and via email at [email protected]. Learn More on Geoffrey M. Parker's contact information.
Has Geoffrey M. Parker been buying or selling shares of Perrigo?: Geoffrey M. Parker has not been actively trading shares of Perrigo during the past quarter. Most recently, on Tuesday, June 13th, Geoffrey M. Parker bought 10,000 shares of Perrigo stock. The stock was acquired at an average cost of $33.06 per share, with a total value of $330,600.00. Following the completion of the transaction, the director now directly owns 25,879 shares of the company's stock, valued at $855,559.74. Learn More on Geoffrey M. Parker's trading history.
Who are Perrigo's active insiders?: Perrigo's insider roster includes Bradley Alford (Director), Svend Andersen (EVP), Eduardo Bezerra (CFO), Rolf Classon (Director), James Dillard, III (EVP), Thomas Farrington (EVP), Alison Ives (EVP), Ronald Janish (EVP), Murray Kessler (CEO), Todd Kingma (VP), Patrick Lockwood-Taylor (CEO), Geoffrey Parker (Director), Grainne Quinn (EVP), Theodore Samuels, II (Director), Raymond Silcock (CFO), Richard Sorota (EVP), and Robert Willis (EVP). Learn More on Perrigo's active insiders.
Are insiders buying or selling shares of Perrigo?: During the last twelve months, Perrigo insiders bought shares 5 times. They purchased a total of 24,540 shares worth more than $675,232.90. During the last twelve months, insiders at the sold shares 3 times. They sold a total of 50,254 shares worth more than $1,411,969.20. The most recent insider tranaction occured on September, 13th when Director Katherine C Doyle sold 8,954 shares worth more than $244,444.20. Insiders at Perrigo own 0.7% of the company. Learn More about insider trades at Perrigo.
Information on this page was last updated on 9/13/2024.

Geoffrey M. Parker Insider Trading History at Perrigo

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/13/2023	Buy	10,000	$33.06	$330,600.00	25,879
3/6/2023	Buy	5,000	$38.05	$190,250.00	15,879
3/17/2021	Buy	2,500	$41.29	$103,225.00	8,441
11/12/2018	Buy	3,000	$65.35	$196,050.00	3,229
11/21/2016	Buy	2,500	$88.75	$221,875.00

Geoffrey M. Parker Buying and Selling Activity at Perrigo

Perrigo Company Overview

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Today's Range

Now: $27.15

$26.80

$27.30

50 Day Range

MA: $25.98

$24.18

$28.21

2 Week Range

Now: $27.15

$23.89

$34.60

Volume

1,232,012 shs

Average Volume

1,783,506 shs

Market Capitalization

$3.70 billion

P/E Ratio

N/A

Dividend Yield

4.05%

Beta

0.48

I was wrong. Dead wrong.

From Porter & Company | Ad